Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

IRLAB Therapeutics AB Class A (6IRA) Stock Price & Analysis

1 Followers

6IRA Stock Chart & Stats

€0.19€0.01(5.68%)
At close: 5:30 PM GMT+1
€0.11€0.115€0.12€0.125May 11Jun 24
Day’s Range
EUR 0.19 - EUR 0.19
52-Week Range
EUR 0.10 - EUR 0.22
Previous Close
EUR 0.18
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 30.19M
Enterprise Value
EUR 95.31M
Total Cash (Recent Filing)
EUR 34.22M
Total Debt (Recent Filing)
EUR 24.20M
Price to Earnings (P/E)
―
Beta
0.17
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet

Lower leverage provides a stronger financial cushion than in prior years and reduces balance-sheet pressure while the company advances its clinical programs. This improvement can support operating continuity and gives management more flexibility to manage funding needs over the next several quarters.

Narrowing Losses

The reduction in losses indicates that the cost base or revenue mix may be moving in a more disciplined direction. If maintained, this trend could slow capital consumption, extend financial runway, and improve the company’s ability to reach future development milestones without proportionally larger funding requirements.

Focused CNS Pipeline

A focused therapeutic strategy can concentrate scientific expertise, capital, and clinical development resources on a defined area of unmet need. Emphasis on Parkinson’s disease and related complications may help build differentiated program knowledge and support partnering potential over time.

Bears Say

Deep Ongoing Unprofitability

Deep losses show that the current development platform is not yet generating sufficient economics to cover its cost base. Continued unprofitability can erode equity over time, increase dependence on financing, and constrain the resources available for advancing multiple clinical programs.

Contracting Revenue

Declining revenue weakens internal funding capacity and suggests that the company has not yet established a reliably expanding commercial or collaboration income stream. Without improved top-line scale, operating leverage is difficult to achieve and future development spending remains financially challenging.

Persistent Cash Burn

Negative operating and free cash flow means the business continues consuming capital rather than funding development internally. This dependence on external financing can dilute shareholders or restrict program activity, particularly if cash generation does not improve alongside clinical progress.

IRLAB Therapeutics AB Class A News

6IRA FAQ

What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.10 and its highest was €0.22 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €30.19M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Aug 26, 2026. The company reported -€0.021 earnings per share for the quarter.
Is IRLAB Therapeutics AB Class A overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 148,632,140 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -€0.021 in its last earnings report. Following the earnings report the stock price went up 1.316%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology